Skip to content

US · IRON · BIOTECHNOLOGY

Disc Medicine, Inc. (IRON) intrinsic value and stock valuation

$75.14as of 2026-11-21 · Mkt cap 3.03B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Disc Medicine, Inc. DCF and intrinsic value

InvestorsCraft values IRON with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IRON’s statements →

Disc Medicine, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 discmedicine.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-212.18M
20202025
Free cash flow
-$-181.33M
20202025
Total equity
$739.8M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-236.02M-$-129.72M-$-91.12M-$-47.48M-$-30.93M
Net income-$-212.18M-$-109.36M-$-76.43M-$-46.83M-$-35.97M
EPSd-$-6.01M-$-3.96M-$-3.42M-$-45.03M-$-44.96M
Operating cash flow-$-180.39M-$-93.93M-$-73.46M-$-42.25M-$-27.53M
Capital expenditure-$-930K-$-510K-$-90K-$-150K-$-70K
Free cash flow-$-181.33M-$-94.43M-$-73.55M-$-42.4M-$-27.6M
Total assets$806.9M$496.8M$368M$200.2M$92.4M
Total debt$1.86M$30M$2.1M$1.33M$7.06M
Net debt-$-89.28M-$-162.43M-$-358.28M-$-193.28M-$-80.98M
Total equity$739.8M$443.6M$345.1M$176.6M-$-64.2M
Cash and short-term investments$791.2M$489.9M$360.4M$194.6M$88M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$170.6M$96.7M$69.3M$33.4M$25.2M
Selling, general and administrative expenses$65.4M$33.1M$21.9M$14M$5.76M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$236M$129.7M$91.1M$47.5M$30.9M
Cost and expenses$236M$129.7M$91.1M$47.5M$30.9M
Interest income$27.8M$21.3M$14.8M$710K$10K
Interest expense$3.61M$570K$0.00$0.00$2.16M
Depreciation and amortization$280K$160K$100K$90K$30K
Ebitda-$-207.94M-$-108.27M-$-76.23M-$-46.74M-$-33.78M
Operating income-$-236.02M-$-129.72M-$-91.12M-$-47.48M-$-30.93M
Total other income/expenses, net$24.2M$20.7M$14.8M$650K-$-5.04M
Income before tax-$-211.82M-$-109M-$-76.33M-$-46.83M-$-35.97M
Income tax expense$360K$350K$100K$0.00$0.00
Net income-$-212.18M-$-109.36M-$-76.43M-$-46.83M-$-35.97M
Weighted average shares outstanding$35.3M$27.6M$22.3M$1.04M$800K
Weighted average diluted shares outstanding$35.3M$27.6M$22.3M$1.04M$800K
Balance sheet
20252024202320222021
Cash and short-term investments$791.2M$489.9M$360.4M$194.6M$88M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$803.9M$493.6M$365.7M$198.5M$90.5M
Property, plant and equipment, net$2.25M$2.32M$2.1M$1.6M$1.75M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.98M$3.16M$2.33M$1.71M$1.93M
Total assets$806.9M$496.8M$368M$200.2M$92.4M
Accounts payable$9.02M$7.95M$12.6M$16.2M$2.56M
Short-term debt$610K$130K$670K$310K$5.32M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$36.6M$23.3M$21.4M$22.6M$13.4M
Long-term debt$1.25M$29.9M$1.44M$1.03M$1.74M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$30.4M$29.9M$1.44M$1.03M$143.2M
Capital lease obligations$0.00$1.68M$2.1M$1.33M$1.65M
Total liabilities$67.1M$53.2M$22.9M$23.6M$156.6M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-510.19M-$-298M-$-188.65M-$-112.22M-$-65.39M
Accumulated other comprehensive income (loss)$960K$290K$0.00$0.00$0.00
Total equity$739.8M$443.6M$345.1M$176.6M-$-64.2M
Total investments$700M$297.5M$0.00$0.00$0.00
Total debt$1.86M$30M$2.1M$1.33M$7.06M
Net debt-$-89.28M-$-162.43M-$-358.28M-$-193.28M-$-80.98M
Cash flow statement
20252024202320222021
Net income-$-212.18M-$-109.36M-$-76.43M-$-46.83M-$-35.97M
Depreciation and amortization$280K$160K$100K$90K$30K
Stock-based compensation$34.3M$16.8M$5.53M$2.09M$510K
Change in working capital$3.53M$3.23M-$-2.95M$2.12M$1.29M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.07M-$-4.68M-$-3.74M$530K$1.31M
Net cash provided by operating activities-$-180.39M-$-93.93M-$-73.46M-$-42.25M-$-27.53M
Investments in property, plant and equipment-$-930K-$-510K-$-90K-$-150K-$-70K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-394.3M-$-292.33M-$-90K-$-150K-$-70K
Common stock issued$472.8M$187.3M$199.1M$53.5M$70K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$473.4M$218.3M$239.4M$149M$89.9M
Net change in cash-$-101.28M-$-167.94M$165.8M$106.6M$62.3M
Cash at end of period$91.4M$192.7M$360.6M$194.8M$88.2M
Operating cash flow-$-180.39M-$-93.93M-$-73.46M-$-42.25M-$-27.53M
Capital expenditure-$-930K-$-510K-$-90K-$-150K-$-70K
Free cash flow-$-181.33M-$-94.43M-$-73.55M-$-42.4M-$-27.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Disc Medicine, Inc.

        Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

        CEO
        John D. Quisel
        Employees
        155
        Beta
        2.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Disc Medicine, Inc. (IRON)?

        InvestorsCraft does not currently publish an intrinsic value for IRON. How the IC value is calculated.

        Is IRON undervalued?

        InvestorsCraft does not publish an undervaluation signal for IRON at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.